CA3153108A1 - Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency - Google Patents
Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency Download PDFInfo
- Publication number
- CA3153108A1 CA3153108A1 CA3153108A CA3153108A CA3153108A1 CA 3153108 A1 CA3153108 A1 CA 3153108A1 CA 3153108 A CA3153108 A CA 3153108A CA 3153108 A CA3153108 A CA 3153108A CA 3153108 A1 CA3153108 A1 CA 3153108A1
- Authority
- CA
- Canada
- Prior art keywords
- certain embodiments
- alkyl
- compound
- hydrogen
- pmm2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962912441P | 2019-10-08 | 2019-10-08 | |
| US62/912,441 | 2019-10-08 | ||
| PCT/US2020/054607 WO2021071965A1 (en) | 2019-10-08 | 2020-10-07 | Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3153108A1 true CA3153108A1 (en) | 2021-04-15 |
Family
ID=75437528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3153108A Pending CA3153108A1 (en) | 2019-10-08 | 2020-10-07 | Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220226323A1 (https=) |
| EP (1) | EP4041219A4 (https=) |
| JP (2) | JP7778686B2 (https=) |
| CN (3) | CN114667139B (https=) |
| AU (1) | AU2020363699A1 (https=) |
| BR (1) | BR112022005895A2 (https=) |
| CA (1) | CA3153108A1 (https=) |
| IL (1) | IL291946A (https=) |
| MX (1) | MX2022004270A (https=) |
| WO (1) | WO2021071965A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL272246B2 (en) | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
| CN113840825A (zh) | 2019-04-01 | 2021-12-24 | 应用治疗公司 | 醛糖还原酶抑制剂 |
| WO2020227430A1 (en) | 2019-05-07 | 2020-11-12 | University Of Miami | Treatment and detection of inherited neuropathies and associated disorders |
| WO2024064147A1 (en) * | 2022-09-20 | 2024-03-28 | Mayo Foundation For Medical Education And Research | Treating congenital disorders of glycosylation |
| WO2025171282A1 (en) * | 2024-02-09 | 2025-08-14 | Landry's Smile, Llc | Methods for treating congenital disorders of glycosylation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007008548A2 (en) * | 2005-07-07 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US20110257233A1 (en) * | 2010-03-19 | 2011-10-20 | Sanford-Burnham Medical Research Institute | Benzoisothiazolones as inhibitors of phosphomannose isomerase |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| WO2013123403A1 (en) * | 2012-02-15 | 2013-08-22 | Sanford-Burnham Medical Research Institute | Theranostics platform and methods of use |
| DK3352754T3 (da) | 2016-06-21 | 2020-12-07 | Univ Columbia | Aldosereduktaseinhibitorer og fremgangsmåder til anvendelse deraf |
| EP3275863A1 (en) * | 2016-07-29 | 2018-01-31 | Universidad Autónoma de Madrid | Compounds for treating congenital disorders of glycosylation |
| IL272246B2 (en) * | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
| CA3110162A1 (en) * | 2018-08-20 | 2020-02-27 | Maggie's Pearl, Llc | Methods for treating congenital disorders of glycosylation |
| CN113840825A (zh) * | 2019-04-01 | 2021-12-24 | 应用治疗公司 | 醛糖还原酶抑制剂 |
-
2020
- 2020-10-07 CA CA3153108A patent/CA3153108A1/en active Pending
- 2020-10-07 CN CN202080070704.XA patent/CN114667139B/zh active Active
- 2020-10-07 JP JP2022521134A patent/JP7778686B2/ja active Active
- 2020-10-07 IL IL291946A patent/IL291946A/en unknown
- 2020-10-07 EP EP20875044.8A patent/EP4041219A4/en active Pending
- 2020-10-07 AU AU2020363699A patent/AU2020363699A1/en active Pending
- 2020-10-07 BR BR112022005895A patent/BR112022005895A2/pt unknown
- 2020-10-07 CN CN202510299373.1A patent/CN120114457A/zh active Pending
- 2020-10-07 MX MX2022004270A patent/MX2022004270A/es unknown
- 2020-10-07 CN CN202510299188.2A patent/CN120093757A/zh active Pending
- 2020-10-07 WO PCT/US2020/054607 patent/WO2021071965A1/en not_active Ceased
-
2022
- 2022-04-07 US US17/715,401 patent/US20220226323A1/en active Pending
-
2025
- 2025-04-07 JP JP2025063234A patent/JP2025100631A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220226323A1 (en) | 2022-07-21 |
| MX2022004270A (es) | 2022-05-03 |
| IL291946A (en) | 2022-06-01 |
| JP7778686B2 (ja) | 2025-12-02 |
| JP2022552831A (ja) | 2022-12-20 |
| WO2021071965A1 (en) | 2021-04-15 |
| JP2025100631A (ja) | 2025-07-03 |
| CN120114457A (zh) | 2025-06-10 |
| BR112022005895A2 (pt) | 2022-06-28 |
| CN120093757A (zh) | 2025-06-06 |
| AU2020363699A1 (en) | 2022-05-26 |
| CN114667139B (zh) | 2025-03-28 |
| EP4041219A1 (en) | 2022-08-17 |
| CN114667139A (zh) | 2022-06-24 |
| EP4041219A4 (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3153108A1 (en) | Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency | |
| US20230121312A1 (en) | Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency | |
| AU2024200537A1 (en) | Compositions and methods for treating galactosemia | |
| US9707219B2 (en) | Losmapimod for use in treating glomerular disease | |
| RU2858535C2 (ru) | Ингибиторы альдозоредуктазы для лечения дефицита сорбитолдегидрогеназы | |
| HK40113967A (en) | Compositions and methods for treating galactosemia | |
| RU2830187C2 (ru) | Композиции и способы лечения галактоземии | |
| HK40030466B (en) | Compositions and methods for treating galactosemia | |
| BR112020001755B1 (pt) | Usos de um inibidor da aldose redutase para o tratamento de galactosemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240913 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240913 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240913 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240920 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240920 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240920 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241003 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241205 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241205 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250219 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250415 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250415 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250416 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250721 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250722 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250722 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250722 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250915 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250915 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251008 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260210 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260211 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260211 |